WO2000034245A3 - Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase - Google Patents

Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase Download PDF

Info

Publication number
WO2000034245A3
WO2000034245A3 PCT/US1999/026809 US9926809W WO0034245A3 WO 2000034245 A3 WO2000034245 A3 WO 2000034245A3 US 9926809 W US9926809 W US 9926809W WO 0034245 A3 WO0034245 A3 WO 0034245A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline form
derivatve
benzoquinoline
inhibitor
alpha reductase
Prior art date
Application number
PCT/US1999/026809
Other languages
French (fr)
Other versions
WO2000034245A2 (en
Inventor
Leland Otto Weigel
Original Assignee
Lilly Co Eli
Leland Otto Weigel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Leland Otto Weigel filed Critical Lilly Co Eli
Priority to CA002354022A priority Critical patent/CA2354022A1/en
Priority to EP99964980A priority patent/EP1149080A2/en
Priority to AU30996/00A priority patent/AU3099600A/en
Priority to JP2000586693A priority patent/JP2002531550A/en
Publication of WO2000034245A2 publication Critical patent/WO2000034245A2/en
Publication of WO2000034245A3 publication Critical patent/WO2000034245A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical agents. More particularly, this invention relates to a novel crystalline form of an octahydro-benzo[f]quinolin-3-one derivative, to pharmaceutical formulations containing this crystalline form as an active ingredient, and to methods of using and processes for preparing the same.
PCT/US1999/026809 1998-12-07 1999-11-10 Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase WO2000034245A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002354022A CA2354022A1 (en) 1998-12-07 1999-11-10 Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase
EP99964980A EP1149080A2 (en) 1998-12-07 1999-11-10 Crystalline form of benzoquinoline-3-one derivative as inhibitor of 5-alpha reductase
AU30996/00A AU3099600A (en) 1998-12-07 1999-11-10 Pharmaceutical agent
JP2000586693A JP2002531550A (en) 1998-12-07 1999-11-10 Crystal forms of benzoquinolin-3-one derivatives as inhibitors of 5α-reductase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11124398P 1998-12-07 1998-12-07
US60/111,243 1998-12-07

Publications (2)

Publication Number Publication Date
WO2000034245A2 WO2000034245A2 (en) 2000-06-15
WO2000034245A3 true WO2000034245A3 (en) 2001-01-18

Family

ID=22337361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026809 WO2000034245A2 (en) 1998-12-07 1999-11-10 Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase

Country Status (5)

Country Link
EP (1) EP1149080A2 (en)
JP (1) JP2002531550A (en)
AU (1) AU3099600A (en)
CA (1) CA2354022A1 (en)
WO (1) WO2000034245A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0532190A2 (en) * 1991-08-21 1993-03-17 Eli Lilly And Company Benzo f quinolinones as 5-alpha-reductase inhibitors
EP0591583A1 (en) * 1991-08-21 1994-04-13 Eli Lilly And Company Benzo (f) quinolinones as 5-alpha-reductase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0532190A2 (en) * 1991-08-21 1993-03-17 Eli Lilly And Company Benzo f quinolinones as 5-alpha-reductase inhibitors
EP0591583A1 (en) * 1991-08-21 1994-04-13 Eli Lilly And Company Benzo (f) quinolinones as 5-alpha-reductase inhibitors
US5541190A (en) * 1991-08-21 1996-07-30 Eli Lilly And Company Benzo(F)quinolinones

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B.A. ASTLEFORD ET AL.: "Resolution of delta-lactams provides access to nonracemic benzoquinolinones: the synthesis of LY300502 and LY300503", JOURNAL OF ORGANIC CHEMISTRY., vol. 61, no. 13, 28 June 1996 (1996-06-28), EASTON US, pages 4450 - 4454, XP002136311 *
BIOORG. MED. CHEM. LETT., vol. 4, no. 11, 1994, pages 1365 - 1368 *
CHEMICAL ABSTRACTS, vol. 121, no. 11, 12 September 1994, Columbus, Ohio, US; abstract no. 133926, A.D. ABELL ET AL.: "Preparative chiral HPLC separation of all possible stereoisomers of LY191704 and LY26611 and their in vitro inhibition of human types 1 and 2 steroid 5alpha-reductases" XP002136312 *

Also Published As

Publication number Publication date
WO2000034245A2 (en) 2000-06-15
CA2354022A1 (en) 2000-06-15
EP1149080A2 (en) 2001-10-31
JP2002531550A (en) 2002-09-24
AU3099600A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
AU2747395A (en) Substituted oxime derivatives useful as pde iv inhibitors
AU2093101A (en) Compositions for efficient release of active ingredients
HUP9802578A3 (en) Phenylacetic acid derivatives, process and intermediates for producing them, fingicide, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients and use thereof
HUP9802822A3 (en) Halobenzimidazol derivatives, intermediates, preparation thereof and microbocide compositions containing these compounds as active ingredients
AU2001278771A1 (en) Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient
HUP0105248A3 (en) Prostaglandin endoperoxide h synthase biosynthesis inhibitors pyridazinone-derivatives, pharmaceutical compositions containing them as active inaredient and process for preparation the compounds
AU4949800A (en) 2-arylpurine-9-acetamide derivatives, process for the preparation thereof, medicinal compositions containing the same and intermediates of the derivatives
WO2001047928A3 (en) Imidazo 1,3,5 triazinones and the use thereof
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
AU2001269198A1 (en) Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
HUP0101766A3 (en) Processes for producing 7-isoindolinequinolonecarboxylic derivatives and intermediates therefor, salts of 7-isoindolinequinolonecarboxylic acids, hydrates thereof, and composition containing the same as active ingredient
AU2002218075A1 (en) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
CA2494321A1 (en) 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
HUP0202988A3 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one derivatives and their use as lipase inhibitors, process for their preparation and pharmaceutical compositions containing them
EP1008345A4 (en) Antiallergic agents
EP1550667A4 (en) Tyrosinase activity controlling agents, process for producing the same and external preparations containing the same
AU2002210632A1 (en) Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same
EP1020444A4 (en) 6-phenoxypicolinic acid, alkylidenehydrazide derivatives, process for producing the same, and herbicide
WO2000034245A3 (en) Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase
PL345309A1 (en) Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
AU7958000A (en) Process for the preparation of oxyiminoalkanoic acid derivatives
AU4845196A (en) 2-sulfinylnicotinamide derivatives, intermediate thereof, process for producing 2-sulfinylnicotinamide derivatives, and medicinal composition containing the same as active ingredient
HUP0003991A2 (en) Serotonin-reuptake inhibitor ciano-indole derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2354022

Country of ref document: CA

Ref country code: CA

Ref document number: 2354022

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 586693

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999964980

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999964980

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999964980

Country of ref document: EP